mouse SOM protein, induces migration and has a protective effect in EC, 1, 2 we have now addressed the question whether SOM1 and SOM3 also regulate essential functions of EC. Here, we demonstrate that both SOM1 and SOM3 are expressed in primary human EC and are regulated reciprocally by physiological levels of NO. Overexpression of SOM1 increases the migratory capacity, inhibits apoptosis, and enhances eNOS activity in EC. In contrast, SOM3 inhibits EC migration, has no antiapoptotic effect, and does not activate eNOS. In contrast to a previous study, 6 we demonstrate that both isoforms are transcriptional activators. Microarray analyses revealed different target gene spectra between the 2 SOM-isoforms, which could explain the opposite effects of these proteins in EC. To further support our cell culture findings, we also investigated the role of SOM1 and SOM3 in vivo in zebrafish embryos. Here, SOM3 induced severe malformations and diminished the number of normally developing animals, whereas SOM1 had no effect. Thus, we conclude that SOM1 has protective functions in primary ECs, whereas SOM3 has deleterious effects in EC and in vivo.
Materials and Methods
Materials and Methods are provided in the online-only Supplement.
Results

SOM1 and SOM3 Are Both Expressed in ECs
We have identified SOM in a screen for antiapoptotic genes in a mammary carcinoma cell line. In ECs, this transcription factor is required for migration. In addition, it induces eNOS phosphorylation in EC, protects these cells against apoptosis in an eNOS-dependent manner, and is required for basal as well as NO-induced migration. 1, 2 In human, 2 additional protein isoforms with different N termini, SOM1 and SOM3, exist, which are derived from alternative splicing of a primary transcript not present in mice, because the mouse genome lacks the corresponding first exon. 6 Their role in EC functions has not been addressed so far. Before assessing functional properties of these proteins, we confirmed expression of both alternatively spliced transcripts in EC by reverse transcription-polymerase chain reaction ( Figure I in the online-only Data Supplement).
Because it is known for several transcription factors that different splice variants have distinct and sometimes opposing functions, we investigated the role of SOM1 and SOM3 in EC.
SOM1 and SOM3 Have Opposing Effects on Endothelial Cell Migration, Apoptosis, and NO-Production
Important properties of EC in the vessel wall are migratory capacity, apoptosis protection, and supply of bioactive NO. To assess the impact of the 2 transcription factor isoforms on EC migration, we expressed SOM1 or SOM3 in primary human EC ( Figure 1A ) and determined their migratory capacity by setting an artificial wound in the EC monolayer and counting the migrated cells. 11 As shown in Figure 1B and 1C, SOM1 dramatically induced migration, whereas SOM3 significantly reduced the migratory capacity of EC after 24 hours. These effects were not attributable to enhanced or reduced proliferation of the cells ( Figure II in the online-only Data Supplement).
In the same experimental setting, overexpression of SOM1 also significantly inhibited apoptosis in EC, whereas SOM3 had no protective effect as measured by annexinV exposure on the outer cell surface (Figure 2A ). These findings were corroborated by the respective changes in the levels of the antiapoptotic protein BCL-X L ( Figure 2B ), which were elevated after overexpression of SOM1, but not changed by SOM3. The antiapoptotic effect of SOM1 was not only observed under baseline conditions, but also, when apoptosis was induced with 7-β-hydroxycholesterol ( Figure 3 in the online-only Data Supplement). One of the most important antiapoptotic and promigratory stimuli in EC is endogenously derived NO produced by eNOS. To assess, whether the protective function of SOM1 depends on eNOS activity, we overexpressed the SOM-isoforms in the presence of the eNOS-inhibitor L-N G -nitroarginine methyl ester (L-NAME), which completely blocked the antiapoptotic effect of SOM1 ( Figure 2A ). A similar effect was observed with respect to the promigratory effect of SOM1 (data not shown). Because overexpression can cause a somewhat artificial situation within a cell, we also knocked down both SOM-isoforms individually to deplete the cells of the respective endogenous proteins. After transfecting EC with isoform-specific, fluorescently labeled siRNAs, we determined that the transfection efficiency was sufficient (>95% transfected cells; Figure IV in the online-only Data Supplement), confirmed the isoform-specific knockdowns by reverse transcriptionpolymerase chain reaction ( Figure 2C ), and measured apoptosis rates. As shown in Figure 2D , knockdown of SOM1 resulted in increased apoptosis, whereas the SOM3knockdown slightly reduced apoptosis rates. After establishing that overexpression and knockdown have a profound influence on EC functions, we asked whether stimuli affecting these functions have an influence on expression of these 2 SOM-isoforms. Therefore, we first established a multiplex real-time polymerase chain reaction approach allowing us to simultaneously detect both transcript variants. To assess the impact of the well-described promigratory and antiapoptotic stimulus NO on expression of SOM1 and SOM3, we treated EC with the NO-donor propylamine propylamine NONOate. We had previously shown that NO increases the migratory capacity of EC 2 and decreases apoptosis rates. 12 In line with these findings, NO induced a nearly 3-fold increase in the level of the SOM1 transcript, whereas the amount of SOM3 mRNA was reduced to ≈70% compared with untreated cells after 18 hours ( Figure 2E ). This reciprocal regulation clearly shows that physiological stimuli change the balance between these 2 isoforms of the transcription factor.
SOM1 Activates Akt1 and eNOS
Because the antiapoptotic effect of SOM1 depends on eNOS, which is constitutively activated by protein kinase B/Akt1 in EC, 13, 14 we analyzed whether the SOM-isoforms have an effect on the activity of both enzymes. Therefore, 24 hours after overexpression of SOM1 and SOM3, we determined . C and D, EC were transfected with siRNAs targeting SOM1 (siRNA SOM1) or SOM3 (siRNA SOM3), respectively. C, Expression of SOM1, SOM2, SOM3, and the housekeeping gene RPL32 was assessed by reverse transcriptionpolymerase chain reaction (RT-PCR). The expected fragment sizes for each transcript are indicated. D, Apoptosis was measured flow cytometrically. Data are mean±SEM (n=3; *P<0.05 versus neg. control). E, Regulation of SOM isoform expression by NO. EC were treated with propylamine propylamine NONOate (PAPA) for 18 hours or left untreated (con). Expression of SOM1 and SOM3 was assessed by multiplex RT-PCR, RPL32 served as control. Top, Representative image of amplification products, the expected fragment sizes for all transcripts are indicated. Bottom, Semiquantitative analysis shown are the levels of the transcripts for the 2 SOM-isoforms normalized to RPL32. Data are mean±SEM (n=3; *P<0.05 versus con). July 2013 the extent of phosphorylation of Akt1 on serine 473 and of eNOS on serine 1179, which translates into the activity of the enzymes. For eNOS, we also measured phosphorylation on threonine 495, which inactivates this enzyme. 15 Corroborating our previous data, SOM1 induced Akt1 and eNOS activation, whereas SOM3 slightly reduced phosphorylation of Akt1, but had no effect on eNOS activation ( Figure 3 ). The increased activity of Akt1 and eNOS as a result of SOM1 overexpression explains the antiapoptotic and promigratory effects of this isoform.
SOM1 and SOM3 Activate Different Target Genes
The most obvious explanation for the opposing effects induced by SOM1 and SOM3 could be the activation of different target genes. Based on 2 hybrid experiments in human 293T cells, it had been proposed that SOM3 is transcriptionally inactive or even a repressor. 6 However, in these experiments, only isolated domains of both proteins were fused to the GAL4 DNA-binding domain. Therefore, it cannot be excluded that other regions of the protein have a function in transcriptional activation, and that fusion to a heterologous DNA-binding domain could mask properties of the full-length protein.
To assess whether SOM1 and SOM3 are transcriptional activators, HEK293 cells were cotransfected with expression vectors encoding full-length SOM1 or SOM3 and a SOM-dependent luciferase reporter plasmid. Here, luciferase expression is controlled by a tandem consensus-binding site for SOM 16 fused to a minimal promoter to avoid interactions with other transcription factors. As a specificity control, we included a reporter, in which critical residues in the SOM-binding sites were mutated ( Figure 4A) . These experiments clearly demonstrated transcriptional activation by both proteins, with SOM3 being the even more potent activator ( Figure 4B and 4C). This, together with the disparate effects on EC migration, apoptosis, and NO-production after 24 hours, suggests that the 2 SOM-isoforms activate different targets genes. Therefore, we analyzed gene expression profiles of EC transfected with expression vectors for SOM1, SOM3, or a corresponding empty vector after 18 hours. Pairwise comparisons revealed that SOM1 regulated 367 genes, and SOM3 regulated 261 genes, when compared with empty vector transfected cells, with only a small overlap of 28 common targets ( Figure 5A ; Tables I and II in the online-only Data Supplement). To validate the microarray data, we chose 2 different targets, which could affect EC functions, the basic helix-loop-helix protein Max interactor 1 (MXI1) and protein kinase B β/Akt2. MXI1 can inhibit Myc-dependent transcription, and Myc has been shown to induce apoptosis in different cardiovascular cells, including EC, 17 smooth muscle cells, 18 and fibroblasts. 19 Therefore, one could assume that MXI1 acts antiapoptotic. Akt2 is a master regulator of all Akt isoforms and, thus, important for apoptosis inhibition and migration. 20 We analyzed the levels of MXI1 and Akt2 in the same setting used for the gene expression analyses. Both proteins were upregulated after overexpression of SOM1 and downregulated by SOM3 ( Figure 5B ). This clearly indicates that SOM1 activates expression of genes coding for antiapoptotic and promigratory proteins, whereas SOM3 suppresses their accumulation.
SOM3 Has Deleterious Effects In Vivo
Finally, we addressed the in vivo relevance of the opposing effects of human SOM1 and SOM3 using zebrafish as a model system. Because the embryos are translucent, they can easily be analyzed through all developmental stages. We injected in vitro transcribed mRNA for human SOM1 and SOM3 in identical molar concentrations into 1-cell stage zebrafish embryos and monitored the resulting phenotypes. The animals were categorized into normal, medium, and severe phenotypes ( Figure 6A ). The medium phenotype is characterized by slightly smaller size, a bent tail, smaller eyes, and obvious apoptosis in the head region. Massively deformed embryos (classified as severe phenotype) have no heads and show an open spinal cord, bifurcated dorsal tails, and massive cell death. SOM1 did not change the embryonic development significantly, when compared with control animals. In contrast, SOM3 injection with the same molar RNA concentration resulted in a dramatic increase in animals with the medium phenotype and severe malformations. Correspondingly, the number of normally developed embryos was significantly reduced ( Figure 6B ). These results demonstrate that not only in primary human cells, but also in a whole animal SOM1 and SOM3 exert different functions.
Discussion
The present study investigated cellular functions of isoforms 1 and 3 of the human transcription factor SOM, which are translated from an alternatively spliced primary transcript. Here, we show that SOM1 and SOM3 are both transcriptional activators, but exert opposing effects on apoptosis and migration in primary human EC, most likely mediated through the activation of different target genes. In addition, SOM3 overexpression, in contrast to SOM1, has detrimental effects in vivo during zebrafish embryogenesis.
Alternative splicing is more a rule than an exception because it affects at least two thirds of all human protein-coding genes, creating an extreme proteome diversity with a limited number of genes. 8, 9 Inclusion or skipping of alternatively spliced exons can be tissue-specific, regulated during development, or in response to physiological or pathophysiological stimuli. One of the most prominent examples for alternative splicing in the cardiovascular system is the pre-mRNA of the vascular endothelial growth factor, leading to several protein isoforms with different properties. 21, 22 Alternative splicing is also a common feature of transcripts encoding transcription factors, with ≈30% of these RNAs in humans being alternatively spliced generating on average 3 protein isoforms. 10 In the vasculature, the Inhibitor-of-Differentiation 3 (Id3) pre-mRNA can be alternatively spliced, creating isoforms of this helix-loop-helix transcription factor, which exert disparate functions. Id3 can promote cell cycle entry and thereby induce smooth muscle cell proliferation by inhibiting p21 WAF1 and p16 INK4 transcription. 23 An alternatively spliced transcript translates into an isoform with a different C terminus (Id3a), which is not detected in normal rat carotid arteries, but abundantly expressed in the neointimal layer after balloon injury, like its human homolog Id3L in carotid atherosclerotic plaques. 24 This isoform, in contrast to Id3, seems to attenuate growth of smooth muscle cell during vascular lesion formation by inducing apoptosis. 23, 24 Unlike Id3 and Id3a, SOM1 and SOM3 are coexpressed in normal tissues and in primary human EC (Ting et al 6 and this study), but similar to Id3, they have opposing effects. Whereas Id proteins sequester basic helix-loop-helix factors, thereby preventing them from binding to DNA and activating transcription, 25 both SOM-isoforms are active transcription factors on their own. The difference in the transcactivation potential observed in our experiments could be ascribed to the luciferase reporter construct used, which only contains tandem binding sites for SOM in front of a minimal promoter. It is long known that the combination of regulatory DNA elements in promoters and enhancers and, thus, the interactions of the respective transcription factors, determine under which conditions a gene is transcribed. Because SOM1 has an extended N terminus compared with SOM3, they might, despite their identical DNA-binding properties, interact with different coactivators or other transcription factors bound to certain promoters, which would also explain the different target gene spectra. SOM target genes have been identified in a microarray screen before by comparing backskin from wild-type and SOM-deficient mice. 26 However, because migration of keratinocytes depends on proliferation, unlike migration of EC, a completely different set of target genes might be induced. In addition, mice do not express homologs of the human SOM1 and SOM3 proteins since the corresponding first coding exon does not exist in the mouse genome and, therefore, these experiments would not have identified isoform-specific targets. We have validated the upregulation of MXI1 and Akt2 by SOM1 in EC on the protein level, which most likely is due to increased transcription, whereas the downregulation by SOM3 might be a secondary effect. Akt2 has been described as a master regulator of all Akt isoforms, 20 explaining the activation of Akt1 and, thus, eNOS observed after overexpression of SOM1. The second validated target, MXI1, belongs to the Mad family, whose members antagonize Myc functions by sequestering Max. In contrast to Myc-Max dimers, which activate transcription by binding to so-called E-boxes, Mad-Max complexes, including MXI1-Max, serve as transcriptional repressors because of their ability to recruit histone deacetylases, thereby inhibiting Myc-dependent transcription. 27 Myc has been shown to induce apoptosis in several cell types of the cardiovascular system, [17] [18] [19] which could, therefore, be blocked by MXI1.
Here, we show that a physiological stimulus promoting migration and inhibiting apoptosis of EC, namely NO, leads to a change in the expression levels of the 2 alternatively spliced SOM transcripts. Whereas the level of SOM1 mRNA is increased, the amount of SOM3 mRNA is downregulated. Together with the observed cellular effects after overexpression or downregulation of these 2 transcripts, this could, at least to a certain degree, explain the promigratory and antiapoptotic effects of NO in human primary EC.
The different SOM-isoforms can dimerize with each other and other members of the grainyhead-like family, 6 which all recognize the same DNA element. 16, 28, 29 It is conceivable that the dimer composition determines which genes are activated. 30 However, the activation of different target genes might also be explained by differential interactions of the 2 SOM proteins with other regulatory factors. In both cases, the consequence of the overexpression of SOM1 or SOM3 would be an altered gene expression profile in EC and zebrafish embryos. The zebrafish genome contains a unique SOM-gene encoding a single protein, which, like the mouse homolog, is related closer to human SOM2 than to SOM1 ( Figure V in the onlineonly Data Supplement). During zebrafish embryogenesis, it is expressed in the gastrula 31 and is a key regulator of periderm differentiation, 32 indicating a role in barrier formation, similar to what has been shown in mammals. 16, 26 Overexpression of SOM3 might, similar to the situation human in ECs, change the transcriptional output in the embryos, leading to an insufficient development of epidermal barriers, which could cause osmotic perturbations explaining the massive deformations observed. Because these events take place before vessel development, it remains unclear whether SOM3 overexpression would also affect the vasculature. Nevertheless, similar to the situation in human EC, the 2 isoforms have different effects in vivo.
Interesting aspects for future studies will be to understand under which other physiological and pathophysiological conditions one or the other SOM isoform is dominantly expressed, and how alternative splicing of the primary transcript is regulated. Because it is also conceivable that not only alternative splicing, but also changes in SOM interaction partners determine which genes are activated under specific conditions, another route of investigation will be to identify and characterize isoform-specific binding partners of the 2 SOM proteins. After having validated 2 proteins differentially regulated by SOM1 and SOM3, it will be important to uncover their exact functions in EC and to further characterize the regulatory networks affected by and affecting the different SOM-isoforms, which could provide clues for therapies aimed at improving endothelial function.
